Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)

Inclusion criteria:

Histologically confirmed NSCLC and measurable disease by RECIST v1.1.
Cohort ALK/RET (will enroll only at selected sites in the US):

  • Participants’ NSCLC must have ALK rearrangement or RET rearrangement.
  • Participants must have ongoing treatment with a standard of care ALK TKI or RET TKI.

Sponsor/Collaborator: BioNTech

Contact and Locations:
Name: BioNTech clinical trials patient information
Phone Number: +49 6131 9084 ext 0
Email: patients@biontech.de
44 Locations: https://clinicaltrials.gov/study/NCT05142189#contacts-and-locations
Cohort ALK/RET will enroll only at selected sites in the US.

Mechanism of action: BNT116 is an investigational mRNA-based vaccine developed by BioNTech targeting six tumor-associated antigens frequently expressed in NSCLC.

Phases: Phase 1

NCT Number: NCT05142189

URL: https://clinicaltrials.gov/study/NCT05142189

Status: Recruiting

Back to clinical trials list
Share